CAR-T: a closer look at the science behind the cells

View exclusive content from the ‘CAR T: a closer look at the science behind the cells’ Kite Satellite Symposium. Gain insights into the factors involved in CAR T-cell therapy response and how this may be used to predict patient outcome.

Hosted during the 15th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland, these sessions included discussion on licensed products, and were organized and fully funded by Kite, a Gilead Company.

How do treatment factors impact CAR T-cell therapy response?

Chiara Bonini, MD, from San Raffaele Hospital, Milan, Italy, discusses the treatment factors that impact patient outcomes in CAR T-cell therapy, as well as the toxicities that may be associated with the treatment.

How do baseline characteristics impact CAR T-cell therapy response?

Max Topp, MD, from the University Hospital of Wurzburg, Germany, outlines important baseline factors influencing a patient’s response to CAR-T therapy within real-world observations, as well as randomized controlled trials. He moves on to discuss the key mechanisms of relapse following CAR T-cell therapy.

Axicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Axicabtagene ciloleucel must be administered at a qualified clinical setting.

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead at safety_FC@gilead.com or +44 (0) 1223 897500.

YESCARTA® (axicabtagene ciloleucel), Kite and the Kite logo are registered trademarks of Kite Pharma Inc © 2019 Kite Pharma, Inc.